45 Recruiting Studies Using Niraparib
Active clinical trials that use this intervention, sourced directly from the NIH registry.
Browse by conditionTrials Using Niraparib
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer
📍 Urology Centers Of Alabama — Homewood, Alabama
Castration-Resistant Prostatic Cancer
View Study & Checklist ➔A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study
📍 University of Colorado Cancer Center — Aurora, Colorado
Cancer
View Study & Checklist ➔Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer
📍 University of Alabama at Birmingham — Birmingham, Alabama
Metastatic Breast Cancer
View Study & Checklist ➔Combination Niraparib and Dostarlimab Therapy for Recurrent or Persistent Uterine Serous Carcinoma
📍 Ohio State University Comprehensive Cancer Center — Columbus, Ohio
Recurrent Endometrial Serous Adenocarcinoma
View Study & Checklist ➔Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma
📍 St. Joseph's Hospital and Medical Center — Phoenix, Arizona
Glioblastoma
View Study & Checklist ➔A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
📍 GSK Investigational Site — Tempe, Arizona
Ovarian Neoplasms
View Study & Checklist ➔A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma
📍 University of Alabama at Birmingham — Birmingham, Alabama
Glioblastoma
View Study & Checklist ➔Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)
📍 University of Arkansas for Medical Sciences — Little Rock, Arkansas
Ovarian Cancer
View Study & Checklist ➔A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer
📍 Urological Associates of Southern Arizona, P.C. — Tucson, Arizona
Prostatic Neoplasms, Castration-Resistant
View Study & Checklist ➔A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
📍 GSK Investigational Site — Anchorage, Alaska
Ovarian Neoplasms
View Study & Checklist ➔Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer
📍 M D Anderson Cancer Center — Houston, Texas
Aggressive Variant Prostate Carcinoma
View Study & Checklist ➔A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.
📍 Duke Cancer Center — Durham, North Carolina
Recurrent Ovarian Cancer
View Study & Checklist ➔Niraparib in Tumors Metastatic to the CNS
📍 Massachusetts General Hospital Cancer Center — Boston, Massachusetts
Metastatic Cancer
View Study & Checklist ➔Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy
📍 UCLA / Jonsson Comprehensive Cancer Center — Los Angeles, California
Advanced Malignant Solid Neoplasm
View Study & Checklist ➔A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
📍 Urology Centers Of Alabama — Homewood, Alabama
Metastatic Castration-sensitive Prostate Cancer
View Study & Checklist ➔Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas
📍 M D Anderson Cancer Center — Houston, Texas
Lung Small Cell Carcinoma
View Study & Checklist ➔A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors
📍 GSK Investigational Site — San Francisco, California
Neoplasms
View Study & Checklist ➔High-Risk Metachronous Oligometastatic Prostate Cancer Trial
📍 University of Maryland Greenebaum Cancer Center — Baltimore, Maryland
Prostate Cancer
View Study & Checklist ➔Niraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal Cancer
📍 Emory University Hospital Midtown — Atlanta, Georgia
Advanced Microsatellite Stable Colorectal Carcinoma
View Study & Checklist ➔A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer
📍 GSK Investigational Site — Phoenix, Arizona
Neoplasms
View Study & Checklist ➔A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer Patients
📍 Massachusetts General Hospital Cancer Center — Boston, Massachusetts
Triple Negative Breast Cancer
View Study & Checklist ➔A Study of Niraparib in People With Soft Tissue Sarcoma Who Have Changes in Their Tumor DNA
📍 Memorial Sloan Kettering Cancer Center (Limited Protocol Activities) — Basking Ridge, New Jersey
Sarcoma,Soft Tissue
View Study & Checklist ➔Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)
📍 Massachusetts General Hospital — Boston, Massachusetts
Metastatic or Locally Advanced Unresectable Solid Tumors
View Study & Checklist ➔A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer
📍 START Mountain Region — West Valley City, Utah
Prostatic Neoplasms
View Study & Checklist ➔A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer
📍 University of Michigan Rogel Cancer Center — Ann Arbor, Michigan
Prostate Cancer
View Study & Checklist ➔Niraparib and Neratinib in Advanced Solid Tumors With Expansion Cohort in Advanced Ovarian Cancer
📍 Virginia Commonwealth University — Richmond, Virginia
Advanced Solid Tumor
View Study & Checklist ➔Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease
📍 GSK Investigational Site — Burbank, California
Neoplasms, Breast
View Study & Checklist ➔Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer
📍 Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington
Anatomic Stage III Breast Cancer AJCC v8
View Study & Checklist ➔Niraparib/TTFields in GBM
📍 Hospital of the University of Pennsylvania — Philadelphia, Pennsylvania
Glioblastoma
View Study & Checklist ➔Niraparib in Combination With Dostarlimab in Patients With Recurrent or Progressive Cervix Cancer
📍 Melvin and Bren Simon Comprehensive Cancer Center — Indianapolis, Indiana
Recurrent Cervix Cancer
View Study & Checklist ➔Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer
📍 Sibley Memorial Hospital — Washington D.C., District of Columbia
Breast Cancer
View Study & Checklist ➔Study of Niraparib and TSR-042 in Recurrent Endometrial Cancer
📍 Tom Baker Cancer Centre — Calgary, Alberta
Endometrial Cancer
View Study & Checklist ➔Niraparib + Dostarlimab In BRCA Mutated Breast Cancer
📍 Yale University Cancer Center — New Haven, Connecticut
Stage I Breast Cancer
View Study & Checklist ➔Niraparib In Recurrent IDH 1/2 Gliomas
📍 Massachusetts General Hospital — Boston, Massachusetts
Low-grade Glioma
View Study & Checklist ➔Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer
📍 Arthur J.E. Child Comprehensive Cancer Centre — Calgary, Alberta
Breast Cancer
View Study & Checklist ➔A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
📍 GSK Investigational Site — Tucson, Arizona
Ovarian Neoplasms
View Study & Checklist ➔Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based Chemotherapy
📍 Dana-Farber Cancer Institute — Boston, Massachusetts
Pancreatic Adenocarcinoma Metastatic
View Study & Checklist ➔Study Evaluating Safety, Tolerability, and Metabolism of Niraparib
📍 Broward Health — Fort Lauderdale, Florida
Ovarian Cancer
View Study & Checklist ➔Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)
📍 M D Anderson Cancer Center — Houston, Texas
Brain Metastases
View Study & Checklist ➔Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer
📍 University of California Davis — Sacramento, California
Prostate Cancer
View Study & Checklist ➔Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Maintenance Treatment For Ovarian Cancer
📍 Sunnybrook Research Institute — Toronto, Ontario
Ovarian Cancer
View Study & Checklist ➔Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
📍 Advent Health — Orlando, Florida
Epithelial Ovarian Cancer
View Study & Checklist ➔Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer
📍 M D Anderson Cancer Center — Houston, Texas
Prostate Carcinoma
View Study & Checklist ➔Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma
📍 Moffitt Cancer Center — Tampa, Florida
Penile Carcinoma
View Study & Checklist ➔Combination Therapy in Cancers With Mutations in DNA Repair Genes
📍 University of California, San Francisco — San Francisco, California
Metastatic Solid Tumor
View Study & Checklist ➔